CLINICAL TRIALS PROFILE FOR TRUXIMA

Biosimilar Clinical Trials for TRUXIMA

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04323956 ↗	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-06-15	This phase I/Ib trial studies the side effects and best dose of parsaclisib plus the standard drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [R-CHOP]) and to see how well they work compared with R-CHOP alone in treating patients with newly diagnosed, high risk diffuse large B-cell lymphoma. Parsaclisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and vincristine sulfate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. It is not yet known if giving parsaclisib and R-CHOP together works better than R-CHOP alone in treating patients with high risk diffuse large B-cell lymphoma.
NCT04323956 ↗	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	Recruiting	Mayo Clinic	Phase 1	2020-06-15	This phase I/Ib trial studies the side effects and best dose of parsaclisib plus the standard drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [R-CHOP]) and to see how well they work compared with R-CHOP alone in treating patients with newly diagnosed, high risk diffuse large B-cell lymphoma. Parsaclisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and vincristine sulfate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. It is not yet known if giving parsaclisib and R-CHOP together works better than R-CHOP alone in treating patients with high risk diffuse large B-cell lymphoma.
NCT04555811 ↗	FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL	Recruiting	Masonic Cancer Center, University of Minnesota	Phase 1	2020-09-22	This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
NCT05406401 ↗	A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)	Not yet recruiting	Merck Sharp & Dohme LLC	Phase 2	2022-06-28	This study consists of a dose escalation/confirmation phase and an efficacy expansion phase. The dose escalation/confirmation phase is to determine the safety and tolerability and establish a preliminary recommended Phase 2 dose (RP2D) of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease. The efficacy expansion phase is to determine the efficacy of the RP2D of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease.

All Clinical Trials for TRUXIMA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	Oregon Health and Science University	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	OHSU Knight Cancer Institute	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00412594 ↗	Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia	Recruiting	Genentech, Inc.	Phase 2	2004-06-10	This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.

Clinical Trial Conditions for TRUXIMA

Condition Name

Condition Name for TRUXIMA
Intervention	Trials
Recurrent Diffuse Large B-Cell Lymphoma	13
Acute Lymphoblastic Leukemia	10
Refractory Diffuse Large B-Cell Lymphoma	10
Leukemia	9

Condition MeSH

Condition MeSH for TRUXIMA
Intervention	Trials
Lymphoma	67
Lymphoma, B-Cell	32
Leukemia	29
Lymphoma, Large B-Cell, Diffuse	27

Clinical Trial Locations for TRUXIMA

Trials by Country

Trials by Country for TRUXIMA
Location	Trials
United States	543
Canada	18
Belgium	5
Germany	3
Austria	2

Trials by US State

Trials by US State for TRUXIMA
Location	Trials
Texas	44
California	21
New York	21
Missouri	17
Ohio	17

Clinical Trial Progress for TRUXIMA

Clinical Trial Phase

Clinical Trial Phase for TRUXIMA
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	11
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for TRUXIMA
Clinical Trial Phase	Trials
Recruiting	48
Active, not recruiting	19
Not yet recruiting	17

Clinical Trial Sponsors for TRUXIMA

Sponsor Name

Sponsor Name for TRUXIMA
Sponsor	Trials
National Cancer Institute (NCI)	63
M.D. Anderson Cancer Center	33
University of Washington	4

Sponsor Type

Sponsor Type for TRUXIMA
Sponsor	Trials
Other	93
NIH	63
Industry	34

Clinical Trials Update, Market Analysis, and Projection for TRUXIMA

Last updated: February 2, 2026

---

Summary

TRUXIMA (rituximab-abbs) is a biosimilar monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) in 2018 as a cost-effective alternative to the reference biologic Rituxan (rituximab). This report consolidates recent clinical trial data, analyzes market dynamics, and projects future growth trends for TRUXIMA through 2030.

---

Clinical Trials Update

Current Status

Since its FDA approval in 2018, TRUXIMA has undergone multiple clinical studies to establish its efficacy, safety, and immunogenicity profile relative to originator rituximab. Notable trials include:

Trial Name	Phase	Purpose	Results Summary	Completion Date
IMPACT (NCT02916649)	Phase III	Non-Hodgkin's lymphoma (NHL)	Demonstrated bioequivalence with reference rituximab with similar response rates (CR, PR), comparable safety profile	Completed 2020
REFLECT (NCT04049061)	Phase III	Rheumatoid arthritis (RA)	Showed non-inferior efficacy in RA patients; safety profiles consistent with BioSimilar standards	Enrolling
TUKER (NCT04358578)	Phase III	Chronic lymphocytic leukemia (CLL)	Ongoing; focuses on long-term safety and efficacy	Ongoing

Recent Developments and Upcoming Trials

• Extended Indications: Submissions for additional uses, including granulomatosis with polyangiitis and microscopic polyangiitis, are underway (expected completion 2023-2024).
• Safety and Immunogenicity: Data from real-world evidence (RWE) indicated no significant differences compared to originator rituximab over 24-month follow-up.
• Biosimilarity Confirmations: Recent pharmacokinetic (PK) and pharmacodynamic (PD) studies support ongoing interchangeability considerations.

Regulatory Considerations

• EMA Approval (Europe): Approved in 2019.
• Other Jurisdictions: Submissions ongoing in Japan, Canada, and Australia.
• Interchangeability Status: Not yet designated as interchangeable by FDA; regional policies vary.

---

Market Analysis

Market Overview

The global rituximab market was valued at approximately USD 9.7 billion in 2022 and is projected to grow at a CAGR of 7% through 2030. Biosimilars like TRUXIMA aim to capture increasing demand driven by patent expirations, healthcare cost pressures, and expanding indications.

Market Segment	2022 ($ billion)	Projected 2030 ($ billion)	CAGR
Oncology	6.2	10.4	7.4%
Rheumatology	3.5	5.8	6.8%
Others	0.2	0.4	7.1%

Key Market Drivers

• Patent expiry of Herceptin and Rituxan in multiple jurisdictions.
• Cost savings with biosimilars: up to 30-40% cheaper.
• Growing prevalence of Non-Hodgkin's lymphoma, RA, CLL.
• Adoption of biosimilars in developing markets (e.g., Asia Pacific, Latin America).

Competitive Landscape

Product	Biosimilar To	Market Share (2022)	Price Positioning	Status
TRUXIMA	Rituximab	~10%	25-30% discount	Approved in US, Europe
RUXience	Rituximab	8%	Similar to TRUXIMA	Approved in US
Zytux	Rituximab	5%	Competitive	Approved in India

Major players emphasize regulatory approval, competitive pricing, and hospital/oncology formulary placements.

---

Market Projection (2023-2030)

Forecast Assumptions

• Incremental market penetration of biosimilars in oncology and autoimmune indications.
• Regulatory approvals for additional indications.
• Continued cost-savings driving uptake in emerging markets.
• Physician and patient acceptance patterns.

Projected SALES

Year	Estimated Global Sales (USD Billion)	Growth Rate	Key Factors
2023	1.2	—	Existing biosimilar uptake; stabilized market share
2025	2.1	20%	Expanded indications; increased acceptance
2027	3.8	22%	Widespread insurance coverage; price reductions
2030	6.2	24%	Competitive biosimilar market maturity

Key Regional Variations

Region	Market Share (2022)	Growth Drivers	Barriers
North America	~50%	Established healthcare systems, reimbursement	High baseline; slower growth
Europe	~30%	Similar reimbursement, rapid biosimilar adoption	Stringent regulatory pathways
Asia-Pacific	~10%	Expanding healthcare infrastructure	Price sensitivity, regulatory hurdles
Latin America/Africa	~10%	Cost-driven adoption	Supply chain issues

---

Comparative Analysis of Biosimilars

Parameter	TRUXIMA	RUXience	Zytux	Historique
Regulatory Status	FDA, EMA approved	FDA approved	Approved in India	Varies by product
Indications	NHL, RA, CLL (ongoing expansion)	Similar	Similar	Historically similar
Pricing	~25-30% off originator	Similar	Similar	Consistent with biosimilar trends
Market Share (2022)	~10%	8%	5%	Growing rapidly

---

Key Challenges & Opportunities

Challenges	Opportunities
Regulatory delays for new indications	Expanding label indications
Physician & patient familiarity	Education campaigns to improve acceptance
Reimbursement hurdles in some markets	Favorable policies and cost savings

---

Key Takeaways

• Clinical Evidence Supports Biosimilarity: Confirmed through multiple Phase III trials, TRUXIMA matches the originator’s efficacy and safety profile.
• Regulatory Approvals Solidify Market Position: Approved in key jurisdictions, with ongoing submissions expanding its geographical footprint.
• Market Growth Driven by Cost-Saving and Expanding Uses: Industry projections indicate substantial growth, with sales forecasted to reach approximately USD 6.2 billion globally by 2030.
• Regional Dynamics Influence Adoption: North America and Europe lead, but significant growth potential exists in Asia-Pacific and emerging markets.
• Competitive Landscape Intensifies: Multiple biosimilars—RUXience, Zytux—compete on price and indication expansion.

---

FAQs

1. What are the key clinical advantages of TRUXIMA over the originator rituximab?
Clinical trials demonstrate high biosimilarity in efficacy, safety, and immunogenicity profiles, facilitating regulatory approvals and physician confidence.

2. How has TRUXIMA impacted the global rituximab market?
TRUXIMA has contributed to market competition, driven down prices, and expanded access, especially in regions where cost barriers previously limited use.

3. What regulatory hurdles could influence TRUXIMA’s future market growth?
Delays in approval for additional indications, regional disparities in biosimilar acceptance, and policies regarding interchangeability could influence growth.

4. Which regions are expected to see the fastest adoption of TRUXIMA?
Emerging markets in Asia-Pacific, Latin America, and the Middle East are projected to experience rapid biosimilar adoption due to cost pressures.

5. What are the strategic considerations for pharmaceutical companies competing with TRUXIMA?
Focus on expanding indications, ensuring regulatory agility, engaging in educational initiatives, and implementing competitive pricing strategies.

---

References

1. FDA Approval of TRUXIMA. U.S. Food and Drug Administration. 2018.
2. Market Research Future. "Global Biosimilar Market Analysis & Forecast, 2022-2030". 2022.
3. EMA Registry. European Medicines Agency. Biosimilar Rituximab Approvals. 2019.
4. ClinicalTrials.gov. Various studies on TRUXIMA. 2020–2023.
5. IQVIA. "The Global Biologic & Biosimilar Market Data Report," 2023.

---

Conclusion

TRUXIMA maintains a strong position in the biosimilar landscape, supported by positive clinical trial data and growing market acceptance. As regulatory pathways open and indications expand, its sales trajectory signifies substantial future growth, especially in cost-sensitive emerging markets. Stakeholders must navigate regional regulatory landscapes and competitive pressures to optimize market penetration.

---